In an interview with Targeted Oncology during the 2019 Kidney Cancer Research Summit, Wayne A. Marasco, MD, PhD, discussed the intricacy of engineering CAR T cells and the early data he has observed with the approach in RCC.
Mack Roach III, MD, discusses the development and evaluation of a multimodal AI algorithm designed to predict prostate cancer outcomes and its performance across racial…
Discover groundbreaking advancements in GI cancer treatments from ASCO 2025, highlighting innovative therapies and improved patient outcomes.
Antonio Jimenez Jimenez, MD, discusses the ACCESS study using HLA-mismatched unrelated donors for peripheral blood and bone marrow stem cell transplants.
Luspatercept-aamt shows significant survival benefits and transfusion independence in lower-risk MDS, reshaping treatment standards in hematology.
During a live event, Heather L. McArthur, MD, MPH, discussed the TAILORx trial in node-negative hormone receptor–positive/HER2-negative breast cancer.
Arturo Loaiza-Bonilla, MD, MSEd, explains the background and findings of the phase 3 DESTINY-Gastric04 trial.
Ruxolitinib shows sustained efficacy and safety in treating steroid-refractory chronic graft-vs-host disease, outperforming standard therapies over three years.
A panelist discusses the evolving role of luspatercept in low-risk myelodysplastic syndrome, highlighting its broad efficacy beyond SF3B1 mutations, its advantage in reducing transfusions and…
Joseph Jacob, MD, discusses the promising impact of TAR-200.
The FDA approves SIR-Spheres Y-90 microspheres for treating unresectable hepatocellular carcinoma, showcasing impressive efficacy and safety in clinical trials.
